HUE032240T2 - Ciklohexilaminok - Google Patents
Ciklohexilaminok Download PDFInfo
- Publication number
- HUE032240T2 HUE032240T2 HUE12781549A HUE12781549A HUE032240T2 HU E032240 T2 HUE032240 T2 HU E032240T2 HU E12781549 A HUE12781549 A HU E12781549A HU E12781549 A HUE12781549 A HU E12781549A HU E032240 T2 HUE032240 T2 HU E032240T2
- Authority
- HU
- Hungary
- Prior art keywords
- propyl
- oxy
- compound
- iodide
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/12—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/33—Polycyclic acids
- C07C63/49—Polycyclic acids containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
- C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (3)
- CSÄCIlira^äMlIlÖE LYefgmk;!;, amelyet si kôVetkeïsÔk-Ptâl Äötoit· exportból válaszúink: M-pkPmHdimsiibbbxeilosdlprop^ N-jp^'||3©ns:öil£3Mlpropi||-N * N •'dietilcikfóhaxáns^ MíN--diπïetiI'N'Ί2''i(2î4í6~trímetüberι¾ol¾oxí)propi1^'Ciklohexânamlr^iut¾'jodιd; ^»PyiP^âte^ôpfeieE^ül^pfôpilj^ll^ôim^icÂ'teânamïniuïit^adid; MpdP-il«Oïben2o!!)D;dtpf0pllkN,^ N " p-lpi4 --dikMrMnzeii) osdfpáöp ilf-M ,Ν~ dlineΰΙρΜ JW;J^«»tiI“îfe^82*œ«ti&wnzofl)a^ N-P^IP d2opri>plèengoiI|oM)propiÎ|''NîN'dirrieülciklohexáriaíinlniuin^ocild:; N''[2"((4-'(terc~btEü)ben2SsII)ö^i||íropíl]-NJN'diroeüicikl;DhesíámsiniinK^mjocud; Ν~(2“{{4-Κ1όΓΪ^ι^ί1}'0^}|)Μρ^Ι^,Ν*άΐΐη«Η1οίΚ^^χά^^ΐπ|ΐΐ;ϊΒ^0ύΙ;ά':ν - (s 3-fliíOrb^^^oi!)í2^Í|p^öpil|“ Μ j ISI- osűicij joííM; ^^i24{24ΐdΠ;^cιrmeti1)b¢ngollïöxijpΓopííj·N>NH'linletUcik]ohexânamirri^rr^'joclIà; |s^ái^tű»K42-{:C2^m»^^|^}pf^gl^<ílM^&exánamíts;feii#^M'; 14 *p»(|0,S*^díMÍrbe3iííöI|©xi)prop3.]]'·N ,N “Etoetílc^löhémnan^kÉp^Mídl •||y.|2^{:(4-ftilbengoil)oxi|^opil!"N>^i->áiái«ÖMMote3íáíiaíiainium~jo^% Il ^ ~|2 ~ {{4 dtritluormetl.!) benÄl) oxi)pf öpilj "ClMohexá:nam!nmmyj odiá; •íS)~N%N'dimeti!~N“(2--{{2,4,6“trirneti!benz:on}03d)propii]''.éidQh«^áfö^mínium-joíjíd; -p:||2 ii-dtee# ; N •^di^tílcikíbh^áíi^tómti^l^ííi ||^E~|iHP^dtei^^Ä^^^p^N,^“dtaüicÄÄexäHamwiuii^d!lä:; ( p).. μ % M'-dímetii-N -j 2-((:2 *4,6- trimeüj benzol i}oxi)propü] - ciklohexánamínm m-jodid ; M -12 - {f 3 4zopropl 1 ben ssoil.) oxi) prop! ] » N»B ·· dimetiieikiöbesxán simlnibm· Jedld ; N-.p-2(2,6'-dikldrbenzoi;)oxiip.ropHl'N>N-'diineidcik]ohexänamirbu?rr':iödid: MBlriiuœ-|odid; Ν~[2~((2,Β·-díkrÍör*ls:e^^^Í!Í)<>x-0p3pajsíí|^M Jf-dimobMMob^^ .M-fi2^->ii^3kl^lSfê^Jt^k:^feot^i-l)ô^i)^^pô]:^H:i.N-d.i«:tts<^i3<iofïie^àLîm^Î^i-a3^^i^dî^:i' dimetiiciklohexánam-mium-jodldí· I^NKiimetii-N^Sditiofer^-karbomBoxiJpropiiJ-dklohex&naroinluffi-jodid; N "(2 -((4 -i2opropiifoen2»iljo^pr«^)^<H-dlsa^ciMÄextotÄ^m'|piÄ:: Ν,Ν - dimetîî ~N-[2 - (( dofên -3 - karboml)o:bjp?ôpi1 j -dMôhexâBâïtiîbum'Jôdiii; N,N-dimetii-N - [2 -(( I -metis -1M-pirroi- 3-kdf bonü)ox jodid; N-|2 ~ ( (bemç>| iaf bqibn-2- karboái) oxilpi? api.] - N ,$ί·- d imp blcikIobe:#i*am Mum·-jodid; N-f2“((2,ő~dímetilbeoizoii)oíd}propil|-N,^:i4-i:ninetíídÍk!ohexánaxrAÍniUíjn"jo<H<iJ'. N>N-dimeüi-lN-[2-i(3-metikiofën“2"karbonilk>xi)propilj-oik1ohexànam.dd«mdO^^Ï ($42^|44£P:rt4bt*d!lbemmiÍ)0xi|:pií^ Μ- (2- ((2,4 ;6~tímet!Ifeaaso^ N>N-dimetil--N-(2-((4-rneMiben2dlI|oxi|pí0pÍI|~€ÍMöhexánámIalaíB-jodidt K^p--C|44t^^fe«'^ito^QÍÍ^^i^-*^íMÍM^ti.&^otae^n«mö5Íum-j©#Íí M-(2--f(2 -etiiben0oil)oxi|propil|-îÇÉ-diPkPliciklob^ N-(2-í(2í4--dio^etiibenaoü}oxi)propiii-b!N-dínietí!ciMohexáiiamiriiurn-jodid; (SkN-fd-lí^'-korc-botMíbemgoilÍOXiipropíIl-N^'dimoükíkiohexánanünmm-jodid; (K|-M-i2'd(4'-(terc-;batil)bpB2;oíl}oxiÍpropiÍ]"N3-dimetilcitóohcxáóam!nl:um-4odid; |BbMd2-((4-(terc-butii|bPd0öll]Pxi;ipxopii|"N:sN-dbru'tsíc)klohexarioodní\Jvn:- broTpid; bromid; J -cikiohexii-1 -42-((2-i^opropilben20Ü)oxi)propiijpirroi^dxt-I-dupptot-dmidé l --oMobexii-1-42-p-i2oi mpíibPxmodldxi) p^pli)pipendirp ! -tom-bf odikl; l"P-((4dtfeí'e-bd£iljbencöiljöxi}pröpü!-l-cM l-|2 (H-{ter*' bHdhben/oîl)oxi}proptt]' 1 '•cik!ohexüpipeyimn>l-íyM«bmmM; 1 ·· [2 •'{(3~klQrbbn2ö|b]:ÍGleP'-2-ka^bömÍ)óXl|propIi-l~cikiPl:MMlpteöÍMm'' I-mm-bromid; és I ''|â»(;(3-Môrfeî1^ô|'î||âpfôn''-|;^|!irbéftâ|ôid}prôpil) - ! - ci kl o hexi 1 p t perid i o - t-lom -bromld. %,M 1· igénypont szerinti wegyilet, amilyet a kb^etkemk által alkotott csoportból választunk: N·· [2 -({2,6 ••dimetüMtjáíöilloxi) propüj -Ν,Ν 'dlmetiiÄlöhexännmifiium^lödki; M'!2"(bcnaoiloidipropil|"N,N'dietíIcíkloh«xó.nam|piuín'kIorid; N.pr2~CC2,Ö~ilmÄÄemoil|oxr)propil|~N,N~dim#lilPikidliiMämamM!tim»iddk1> Ν' · [2 {(2 iliiorbenzoil)οχι)propi ί] -Ν,IN-dimeülcMohexánaminium-jodidt N- i2~((2~klôrben^oï1)oxi|propîî]"N',N~dimetüciklahexâp^iâ5Siîni.um"jodid|:: N--|2-'((2pt'dikiôrbena:oii)oxt)pn>pill--NbN^'-dimtdilciklo!PkxÉriarrboivun-'jddid; ^N-diHietibN-pylp-metilbei^oiîlôîdlpmpiiheMohiS^iiBiamînùtm-jdÂd; Μ* [2 - (|2::<4KOptöplibepKbl!i oxi) propii) · N s N •diynpdtclklodoxànaminmTp^pdM; Μ "|2 " ( :(4 - I tere-' bbtllj b ®nzóii|öxi|prüpí!j-Μ, :^dteetiÍtíMdkéxátíd*Hlíítem?-jpsÉíd| N'· (24(4*Morb^^ - Ν 3-dimMÍicidöbex^ ^*[2-{{3-0iiorben^n)oxi)propit]-N4N-dim#ltótófertö.amtefem-|#iiMy N'(2b;4-lluor-2-(trilluomieÜi}benzoil)oxi)propU|bbN-dimeiiiciklohexánarnio.ium·· jodid; N>N-dimetikINkf2"|13"|fcridn0ymetil)beu^ N-1' 2 ~ ((2'(triflr^rmrrieiil)benzoil}oxi)pro|-.îij.|·· Ns N-dlioetiiciklohcxânamlniom'jodid; Ν,Μ-Diïnebklf - [2-((2 'nItroben2oii)oxdpropil]-'Ciklohexânaiixmmmpodid; N-(2-((3 s 5'diklôrbenzoil}oxi)propilj-N, N-dimetiíciMohexánamm ip m-j odid; i-(àk|(4-eUibepsioÔ|p^)prqpÛ|-Âj^“4^#tîlci^îôh^iriam!ftium-jodkl; M5H-dfmeäkM-[2-(id-(tril1uornmti))ber^oil)oxi)propil]-cmlohcx0Tiarnirdumd0Ö3di (S)"N>N"dimetil"N-[2"((2s4v6'Sitrirpißiti||)eiigoil)oxi)prö:pll']-'Cikiobexäriaminjum-jodidi (S)-N-[2-{(2:6-dírnetilbtaisoi!)oxt)propÍl]-NJN-dimetilcikjohexánamirüum'jodid; (ipN-pHp J-bipmtIbenzQli|©xkpropil]^ (R}-H3~<IiïTi«tll~M-i2-{{2>450^metilben«oii)«X))propil)--cikiohexànaniiîi;ràm-'jo4id.‘ ]M-42-{(3-kôpropilber5^oiI)oxispropil]'-MvN'-d:5metiidk]ohexànâ.mînium-jodid; H- [2 ~ {(2, § - dMórbexxxoü) oxi)propil j -- H, JM -ciimet üci klohexána mini um-j-ôdiâ; id|iN-'d:lnietil''N''|2-di2p4;6<4:rin.itaili'XJ.n:;oil}oxi):propil]tetrahidro-2H-pi:rän-4~ am in i u m - j od i d ; N-ld-llÄjd-diMörbenaöiiiomipropili-MjN-dimetliciklöhnxänamininmdlodid: N-f 2 - f {ciMoh exánkar boxxll j oxi ) propilj ~ H, N · d le ti I ciMoHexanaxxxi xd um -jodi d; N ' 12 ~ (|3 - kl ór benxojbj hóién-- 2·' kafboali) oxi) propii] ~ N? N « d imeii i ciki ohexán ami n i u m -j od i d ; H, N -d ime tü -N - (2 ~ ({tíóien~2 - karbon ii)oxi) propü] ~cikiöii.exánam.lniiimp odid ; N~[2~{{4dnopropiIbenaoíi)om)propi:11-MiN--dimetilcMohoxá:namÍmn:in--Jod.id; N»M-'d:lmetíl“M“[2~(|tipfer~3'~karbopI!)OTlpropiÍ}“CÍkio.hexánarninhirn-jodiá; N,N~dixPdtil"N" p~({ I "tïietil· '1 H'pírr(d.->3'kárfoónll)nxi|propliJ -•eikiohexixxamininrn-· jodld: 14--(2-- ({bensői b ] bőién - 2~ karbon!!) oxiipropii] - M, N "dime tikiklo hexánannrmx m-jodicl; N « (2 - {(2 f ö "dimedl bepxoil) QXi)pf opil] --N ; N:; 4-tpim.dtikákkfbPkámmíPium~iddid;í N»N"diíBetil-N~í2"({3»m:etütiüfén-2-karbomii}oxj}prppíi)"dikiöhe-H:áBaaiíniup3.d)ödid;· i2"|2"({4"(terC”b'Ui'il)benaoii)oxi)propil]~N,N.r4~trirrKd'iIclkiohexa.rxanxiniuni"iodld; NtNparimeübiM"j2d(23;6~mmeülbenaoil)öXi)propil]"C:ikÍohexánannninmpodid; N"pk(2p-dÍmetiÍboxx20ÍI}oxiieüÍ]"N!N-Qinxo:dIciMöh:exáiraxrxmiumpodíd; H ' |2 ~ ((2,4,6 - trim etil bensőit) oxi) e bi j ~N, M - d imo tücik l ohe xán aromxnm -j oáiá ; N;N~dimetil"]2"i2d{4-medlbenxoiI|oM)propii]"Oikiôbexâixaxrnnium'-jodid; h -(2-((4-(terc-botii) ben2ioü).o3d)etü!---M > kbdinmtiiciMöhexánaxxnniixm-jodid; Nr-[2~{^2"eDlbenxoi]}Oxi}propil]-NjN"d.ivnedldkiohex&namvniurn''jodid; N"['2"d'2a4"dintetiltn;xxax>il;«3xi}propii.|"N\k'Xilrnetikxiklohexaxxafninkitxx-jodid: (Sp N~ [2 - {(4·· (tere-· hti iilVhenxoil) oxi) prepái] - NN« dlmetileiklxxbexáxxapinxip m -Jodld ; (R) -- N -4 2 -- ( (4 4 terc-b u til) benzoíl) oxijpre xpilj -- ét s H -d Imetil ei klód exáxiammi urna od id ; (S) --N--(2--((4--(terc-'bixdl) benxolij oxi Vpropiij--H,N”dimêdlelkiobexànaxxxmmm'-bromid; és (R> g, re buul)ht nrcljfoxgpropilbFIMi» bromid, 3* kompozíció, amely tartalma« 1, vagy 2< igénypontban említett vegyöletet 4* A 3, igénypont szerinti kompozíció, amely tartalma« továbbá TRPV1 receptor aktivátort. 5, A 4. Igénypont szoíidti kompdiM^. Ä m eralitett ERPVl receptor aktivátort a kapszaidn, dihidrokapsxaictrg nordihktrokapsz&icin, lidokain, arükain, prokain, tetrakam. mephnkain, bupivtikain, eugenoi, kámfor. Mótómazol, ^-iirdchiddndlvatiüîâtaïn, anardannd, â-.amippdtoxidlfeni.1 -hor|$, AM4Q4i realptlaratöxln, fórból-12-'fenllaœtào-i3"aeeum-20"bomovamiiàt? oivaaik Hmleoiidppamin, NmrachidordldopaM:m:i d^-jodreamlieratoam;,: Ers R-acileiaifoiaMin, ipoxigenâx-'SMrmazéfo nonivamid:, tetrahiríroizpkipoiin irdnbitof etetem csomós pepiid ztesameyia.nn<te> H-(2--{3»4 -âm0$lM®iâÎ}^ {piva|iailôsà)propii]“-2"(4"f2"amlnoetoxi)-3"metoxifenU|acetaï?i.id, Ν"|'2"|3>4" dlmedlbermill-S'-tpivaloilaxiSpropill'N’-iAdbdroxl-'d'rnetoxibenribtiokarbarald; hldboxte'-sanshdoir 2-ammoetoxidiíen.ü-borát, Ml-aliogábt dleítglngeroL oleilebogao!, aprindin : bemmkain, foutakalrg kokainé, dibukaln, enkainid, mexileün, oxetakam. prilokain, propara.ka.im proka.ina.mld, n - ace faprokain amid, kiórprokain, diklonin, etidokain, levobupivakain, ropivakain, dkiornetikain, dimetokain. propoxikain, trimekain és a szimpokain által alkotott csoportból választjuk. 6. A 4. igénypont szerinti kompozíció, ahol az említett TRFV l receptor aktivátor a Mókáim f.i 4« igénypont szerinti kőin pozíció, amely betegnek történd orális, intramuexkulárls. rektális, kutan, rsxnhkmân, fopikábs, transxdermális, szubiingvfíifo paxâlls, vagináik epidprilisyagy okolirip adagolásra vart formuláivá. 8. A 4. Igénypont szerinti kompozíció, amely lartaimazxa az említett vegyüfotet legaMfeb 3,2 % mennyiségben, vagy előnyösen az említett vegyülete? legfeljebb 5 % mennyiségben, vagy az említett TRPV1 receptor aktivátort 2 % me n nyisd gben.
- 9, Az 1 vagy 2. igénypont szerint! vegyülni M TERVI receptor aktivátor betegben írj dalom vagy viszketés kezelésében való alkalmasáéra. %§s rn l, «y 2, liénypbhl szerinti tegfüM heiégben M|daioíb vagy viszketés kezelésére való alkalmazásra, il, M i, vagy 2. igénypont aserintivogyblot tülmuködé hólyag kezelésében való alkalmazásra. m* M 1. vagy 2, igénypont ezerint! vegyilet inters ccalm bélyaggyullábis kezelésében való alkalmazásra, Ä A 9. Igénypont szerinti vegyület és a TRPV! receptor aktívátor fájdalom. vagy viszketés kezelésében való: alkalmazásra, ahol a TERV l receptor aktlvátort az emlitett vegyület előtt atíagoljnk, vagy ahol a TRPV 1 receptor aktivátort és az említeti: vegyhletet együtt adagoljuk. 14, A 9, igénypont szerinti: vegyület és a TRPV 1 receptor aktívátor vagy a 10. igénypont szerinti vegyniet íipálam vagy viszketés kezelésében való: alkalmazásra, ahol az emlitett f|dáioni: neüropátíás lljdalonk gyitiladäsoo fáj dalom, nocicoptiv fájdalom, prooedurális Ipjáalom, vagy ahol az emlitett fájdalmat oyeiöesörák, írritábills bél szindróma vágy Miopatlás nenropátia okozza,
- 15, A E igénypont szerinti vegyniet és a. TERVI receptor akdvátpr vagy a 10, igénypont szerinti vegyület iájdálout vagy viszketés kezelésében. való alkalmazásra, ahol az emlitett adagolás orális, intrarnuszkuláris, rektálls, kután. szubkután, iopikális, Iranszdermális, szublingvális, nazális, vaginába, epkluráits vagy okuláris. 1#, A 9. igénypont szerinti vegyület és a TRPV 1 receptor aktívátor fajdalom \?agy viszketés kezelésében való alkalmazásra, ahol o.z említett TRPV.! receptor aktívátor és az említett vegyület aránya legalább körű!belül 4:1, és előnyösen, ahol az emlitett ΤΚΡΥΊ. receptor aktivá tor és az emlitett vegyület aránya 1: .10 és 10:1 közötte If* A IL vagy 12. igénypont szefthti vegyűlet túlmúkedo hólyag vagy totersticiális hólyaggynlladás keselésében való alkalmazásra, ahol az említett adagolás aj az említett vegyíHat feddagba vagy orotheiiumba. torténo kozvetlén becseppeniése útján, előnyösen hatoanyagtoldátkéni: bëtmppenim. tőriámk, vagy b| aboi az endltett vegyűlet ernlitett hólyagba vagy msetlmlmmha iëmênô behelyezésével nyújtod' h&tóanyag-Ieadásó készítményként, elinyesen. hatóanyagot tartalmazó: tartályok, hatóanyaggá!: bevont anyag, hatóanyaggá]/ Impregnált anyag vagy Mposzomáíis &&%émy&g»ké&á*mém· tormájában történik, vagy ej ahol az említett vegyütetnek as orotheöotnba törkéno közvetlen, tojektálásávai történik. 18< A 9. Igénypont szerinti vegyűlet és a TRPV1 receptor aktivátor fájdalom vagy viszketés kezelésében való alkäiarazäsr&i ahol azeoilltett TRPVl receptor aktivatort a Mpszaiebp díhldrofcapszaicim nordihídf okapszaicim iiáokaInJ: arhfcain, próbáin., íelrakáih, mepivlkain, bnpívikáih, eagenol, kámfor,, kloínrnazol, .|^~-atacÉàdQ»^ivœÙkmiB. anandafoid, 3mniinoetPkidifehi:l->börit? AM4Ö4, reslniíeratöxin, fórból'· 1á-feaiiaeetáL 13-aoetái:- 20 «hPÄyapÄt». olvami, Mtolaoiídopamim M--araei'hdonilboparrhn, byjódreainiferatoxto,. Cm Hu aciietanolamm, üpoxlgenáz-származék, nomvamid, tetrahidroízokínolin inhibitor ci sete-n csomós pepbd ssirsavaeüamidja> N''i2-{3í4'dlmetilbenzli)''3:' fpfoaloíloxűpropilj '2"j4-f2-'anármetoxi)'-3 -m.etoxifenli]acet.amid, Ν-·|2'(3.4-dImetlibenailj'3'ipIvaMl:otojpröpiij:'be(4to.idrom'-3~metoxihenáiÍjttokarb hídroxi··o.· sanshool* Ibaa.rniraoetoxidifcnd-'borát, lö-shogaol, oleügüigeroi, olelishogaoi, aprindin, benzokain, hn to.ko.irp kokainé, dibukain, enkamld, mexüetin, oxetakain,, pniokain, proparakaim prakainanűd, n-aoeMprokamophd, klóíprökain, diklonin. eüd okain, ievobupivakain, ropiva.kam» cikiometikam, dimetokairg propoxikaio, tiimekam és Sármpokala altat ametott csoportból választjuk,
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161550489P | 2011-10-24 | 2011-10-24 | |
US201261683519P | 2012-08-15 | 2012-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032240T2 true HUE032240T2 (hu) | 2017-09-28 |
Family
ID=47143310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12781549A HUE032240T2 (hu) | 2011-10-24 | 2012-10-24 | Ciklohexilaminok |
Country Status (8)
Country | Link |
---|---|
US (2) | US8685418B2 (hu) |
EP (1) | EP2771320B1 (hu) |
JP (2) | JP6495654B2 (hu) |
CA (1) | CA2853279C (hu) |
DK (1) | DK2771320T3 (hu) |
ES (1) | ES2596215T3 (hu) |
HU (1) | HUE032240T2 (hu) |
WO (1) | WO2013063127A1 (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685418B2 (en) * | 2011-10-24 | 2014-04-01 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
PT2956440T (pt) | 2013-02-08 | 2018-05-08 | Gen Mills Inc | Produtos alimentares com baixo teor de sódio |
US8975595B2 (en) | 2013-04-12 | 2015-03-10 | Becton, Dickinson And Company | Automated set-up for cell sorting |
JP6479543B2 (ja) * | 2015-04-09 | 2019-03-06 | 株式会社東芝 | 酸性ガス吸収剤、酸性ガスの除去方法および酸性ガスの除去装置 |
JP2021524465A (ja) * | 2018-05-22 | 2021-09-13 | ジービーエス グローバル バイオファーマ,インコーポレイテッド | Trpv1モジュレーションに使用するためのカンナビノイド及び/又はテルペン |
EP3886827A4 (en) * | 2018-11-30 | 2022-08-31 | Asana BioSciences, LLC | FORMULATIONS, METHODS, KITS AND DOSAGE FORMS FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT |
BR112022008575A2 (pt) * | 2019-11-06 | 2022-08-09 | Nocion Therapeutics Inc | Bloqueadores de canal iônico carregado e métodos para uso |
JP7470842B1 (ja) | 2023-04-04 | 2024-04-18 | 公立大学法人奈良県立医科大学 | 間質性膀胱炎・膀胱痛症候群の診断方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069309A (en) | 1972-09-19 | 1978-01-17 | Avon Products, Inc. | Cationic skin substantive sunscreen composition and method |
US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
DE3415103A1 (de) | 1984-04-21 | 1985-10-31 | Bayer Ag, 5090 Leverkusen | Verfahren zur fluoreszenzloeschung und neue kationische aromatische nitroverbindungen |
DE3418672A1 (de) | 1984-05-19 | 1985-11-21 | Basf Ag, 6700 Ludwigshafen | Basische azofarbstoffe |
DE3502693A1 (de) | 1985-01-26 | 1986-07-31 | Basf Ag, 6700 Ludwigshafen | Basische azofarbstoffe |
DE3602016A1 (de) | 1985-12-05 | 1987-06-11 | Bayer Ag | Pyri(mi)dyl-oxy- und thio-benzoesaeure-derivate |
US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US5575815A (en) | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
US5633002A (en) | 1988-10-04 | 1997-05-27 | Boehringer Ingelheim Gmbh | Implantable, biodegradable system for releasing active substance |
US5411738A (en) | 1989-03-17 | 1995-05-02 | Hind Health Care, Inc. | Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
AU651654B2 (en) | 1992-01-14 | 1994-07-28 | Endo Pharmaceuticals Solutions Inc. | Manufacture of water-swellable hydrophilic articles and drug delivery devices |
US5266325A (en) | 1990-09-28 | 1993-11-30 | Hydro Med Science Division Of National Patent Development Corp. | Preparation of homogeneous hydrogel copolymers |
US5464719A (en) | 1994-12-07 | 1995-11-07 | Eastman Kodak Company | Toners and developers containing ammonium tetrahaloferrate salts as charge-control agents |
JP3471122B2 (ja) | 1995-04-26 | 2003-11-25 | アルケア株式会社 | 医療用粘着配合物 |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
SE508357C2 (sv) | 1996-01-02 | 1998-09-28 | Kay Laserow | Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta |
SE9604751D0 (sv) | 1996-12-20 | 1996-12-20 | Astra Ab | New therapy |
US6039967A (en) | 1997-04-03 | 2000-03-21 | Point Biomedical Corporation | Intravesical drug delivery system |
US6623040B1 (en) | 1997-09-03 | 2003-09-23 | Recot, Inc. | Method for determining forced choice consumer preferences by hedonic testing |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
US6413987B1 (en) | 1999-06-10 | 2002-07-02 | Bridge Pharma, Inc. | Dermal anesthetic agents |
US20040214867A1 (en) | 1999-12-15 | 2004-10-28 | Choi Lewis Siu Leung | Quaternary salts of n-substituted cyclic or acyclic amines as pharmaceuticals |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
IL155374A0 (en) | 2000-10-13 | 2003-11-23 | Alza Corp | Apparatus and method for piercing skin with microprotrusions |
US7537795B2 (en) | 2000-10-26 | 2009-05-26 | Alza Corporation | Transdermal drug delivery devices having coated microprotrusions |
US6766319B1 (en) | 2000-10-31 | 2004-07-20 | Robert J. Might | Method and apparatus for gathering and evaluating information |
CA2789114C (en) | 2001-11-01 | 2014-03-25 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
SI2561860T1 (en) | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
US7858110B2 (en) | 2003-08-11 | 2010-12-28 | Endo Pharmaceuticals Solutions, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
WO2006036936A2 (en) | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
CA2587780A1 (en) | 2004-11-18 | 2006-05-26 | Transpharma Medical Ltd. | Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents |
DE102005032848A1 (de) | 2005-07-14 | 2007-01-25 | Robert Bosch Gmbh | Verfahren und Vorrichtung zur Fahrerunterstützung |
CA2622418A1 (en) | 2005-09-23 | 2007-04-05 | Bridge Pharma, Inc. | Indanylamines and their use for local anesthesia and chronic pain |
ES2402789T3 (es) | 2006-11-20 | 2013-05-08 | President And Fellows Of Harvard College | Métodos, composicones y kits para tratar dolor y prurito |
US20110086818A1 (en) | 2008-03-11 | 2011-04-14 | Presidents And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritus |
WO2010036878A1 (en) * | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
EP2352544A4 (en) | 2008-11-07 | 2013-12-25 | Combinent Biomedical Systems Inc | DEVICES AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF DISEASES |
US20110046600A1 (en) | 2008-12-05 | 2011-02-24 | Crank Justin M | Devices, systems, and related methods for delivery of fluid to tissue |
JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
CN107540599B (zh) | 2011-02-18 | 2021-06-04 | 阿萨纳生物科技有限责任公司 | 氨基茚满化合物及其治疗疼痛的用途 |
US8685418B2 (en) * | 2011-10-24 | 2014-04-01 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
-
2012
- 2012-10-24 US US13/659,694 patent/US8685418B2/en active Active
- 2012-10-24 EP EP12781549.6A patent/EP2771320B1/en active Active
- 2012-10-24 ES ES12781549.6T patent/ES2596215T3/es active Active
- 2012-10-24 JP JP2014538934A patent/JP6495654B2/ja active Active
- 2012-10-24 WO PCT/US2012/061703 patent/WO2013063127A1/en active Application Filing
- 2012-10-24 CA CA2853279A patent/CA2853279C/en active Active
- 2012-10-24 HU HUE12781549A patent/HUE032240T2/hu unknown
- 2012-10-24 DK DK12781549.6T patent/DK2771320T3/en active
-
2014
- 2014-03-20 US US14/220,381 patent/US9180115B2/en active Active
-
2017
- 2017-05-31 JP JP2017108579A patent/JP6835668B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CA2853279A1 (en) | 2013-05-02 |
EP2771320B1 (en) | 2016-06-22 |
US8685418B2 (en) | 2014-04-01 |
US9180115B2 (en) | 2015-11-10 |
JP2015501320A (ja) | 2015-01-15 |
JP6835668B2 (ja) | 2021-02-24 |
WO2013063127A1 (en) | 2013-05-02 |
JP6495654B2 (ja) | 2019-04-03 |
US20140213552A1 (en) | 2014-07-31 |
CA2853279C (en) | 2021-03-23 |
EP2771320A1 (en) | 2014-09-03 |
JP2017214376A (ja) | 2017-12-07 |
ES2596215T3 (es) | 2017-01-05 |
US20130101667A1 (en) | 2013-04-25 |
DK2771320T3 (en) | 2016-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2771320T3 (en) | Cyclohexylamines | |
AU2020277232B2 (en) | Aminoindane compounds and use thereof in treating pain | |
US9375423B2 (en) | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |